Who are busulfan (Busilvex ®)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Paraplatin, Cytoxan (Lyophilized), IFO, Melphalan (Mel), Cyclophosphamide (CY), Mitomycin-C sponge.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/busulfan-busilvex.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

busulfan (Busilvex ®) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

busulfan (Busilvex ®) (busulfan (Busilvex ®)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkylating agent. Area: Oncology.

phase 3 Alkylating agent Oncology Small molecule Live · refreshed every 30 min

Target snapshot

busulfan (Busilvex ®) (busulfan (Busilvex ®)) — PETHEMA Foundation. Busulfan is an alkylating agent that interferes with DNA replication, leading to cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
busulfan (Busilvex ®) TARGET	busulfan (Busilvex ®)	PETHEMA Foundation	phase 3	Alkylating agent
Paraplatin	Carboplatin	MYLAN SEIYAKU Ltd	marketed	Platinum-containing alkylating agent	DNA	1989-01-01
Cytoxan (Lyophilized)	cyclophosphamide	Baxter	marketed	Alkylating agent	Tumor cell DNA	1959-01-01
IFO	IFO	Italian Sarcoma Group	marketed	Alkylating Agent	DNA
Melphalan (Mel)	Melphalan (Mel)	Institute of Hematology & Blood Diseases Hospital, China	marketed	Alkylating agent	DNA
Cyclophosphamide (CY)	Cyclophosphamide (CY)	Nanfang Hospital, Southern Medical University	marketed	Alkylating agent	DNA (non-specific alkylation)
Mitomycin-C sponge	Mitomycin-C sponge	University of California, San Diego	marketed	Alkylating agent	DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2035-06-26 — Cytoxan (Lyophilized) · 9662342 · Formulation · US
2035-07-13 — Cytoxan (Lyophilized) · 10849916 · Formulation · US
2035-12-01 — Cytoxan (Lyophilized) · 11382923 · Formulation · US
2036-02-15 — Cytoxan (Lyophilized) · 12329767 · Formulation · US
2036-02-15 — Cytoxan (Lyophilized) · 10993952 · Formulation · US

Sponsor landscape (Alkylating agent class)

Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
M.D. Anderson Cancer Center · 2 drugs in this class
Nanfang Hospital, Southern Medical University · 2 drugs in this class
Asahi Kasei Pharma Corporation · 1 drug in this class
Baxter · 1 drug in this class
BeBetter Med Inc · 1 drug in this class
Astellas Pharma China, Inc. · 1 drug in this class
Children's Cancer Group, China · 1 drug in this class
Federal Research Institute of Pediatric Hematology, Oncology and Immunology · 1 drug in this class
Celyad Oncology SA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). busulfan (Busilvex ®) — Competitive Intelligence Brief. https://druglandscape.com/ci/busulfan-busilvex. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab